Literature DB >> 21412060

CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.

Albert K Minga1, Charlotte Lewden, Delphine Gabillard, Germain I Bomisso, Thomas-d'aquin Toni, Arlette A Emième, Vincent Yapo, André Inwoley, Roger Salamon, Xavier Anglaret.   

Abstract

BACKGROUND: WHO recommends initiating combination antiretroviral treatment at the minimal CD4 cell threshold of 350 cells/μl. In sub-Saharan Africa, the time for a recently infected patient to reach this threshold is unclear.
METHOD: We estimated the probability of reaching different CD4 cell thresholds over time in the ANRS 1220 cohort of HIV-1 seroconverters in Côte d'Ivoire. CD4 cell slopes were estimated using a mixed linear model. Probabilities of crossing the 350 and 500 cells/μl CD4 cell thresholds were estimated by the Kaplan-Meier method.
RESULTS: Between 1997 and 2009, 304 recent seroconverters have been enrolled in the Primo-CI cohort (62% men, median baseline age 29 years and median time since the estimated date of seroconversion 9 months). The probability of having a first CD4 cell count below 500 cells/μl was 0.57, 0.72, 0.79 and 0.84 at study entry, 2, 4 and 6 years, respectively. For a first CD4 cell count below 350 cells/μl, these figures were 0.29, 0.40, 0.55 and 0.67. The time for 75% of patients to reach the threshold was 3.0 years for 500 cells/μl and 7.0 years for 350 cells/μl.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412060      PMCID: PMC3921664          DOI: 10.1097/QAD.0b013e32834625d3

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.

Authors:  Reuben M Granich; Charles F Gilks; Christopher Dye; Kevin M De Cock; Brian G Williams
Journal:  Lancet       Date:  2008-11-27       Impact factor: 79.321

2.  HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.

Authors:  C Costello; K E Nelson; V Suriyanon; S Sennun; S Tovanabutra; C M Heilig; S Shiboski; D J Jamieson; V Robison; K Rungruenthanakit; A Duerr
Journal:  Int J Epidemiol       Date:  2005-02-28       Impact factor: 7.196

3.  Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire.

Authors:  Albert Minga; Christine Danel; Yao Abo; Lambert Dohoun; Dominique Bonard; Ali Coulibaly; Julien Duvignac; François Dabis; Roger Salamon; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2007-02       Impact factor: 9.408

4.  Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.

Authors:  Peter J Dodd; Geoff P Garnett; Timothy B Hallett
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

5.  Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART.

Authors:  Roberto Muga; Inmaculada Ferreros; Klaus Langohr; Patricia García de Olalla; Jorge Del Romero; Manuel Quintana; Ignacio Alastrue; Josefina Belda; Jordi Tor; Santiago Pérez-Hoyos; Julia Del Amo
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

6.  Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.

Authors:  Siaka Toure; Bertin Kouadio; Catherine Seyler; Moussa Traore; Nicole Dakoury-Dogbo; Julien Duvignac; Nafissatou Diakite; Sophie Karcher; Christophe Grundmann; Richard Marlink; François Dabis; Xavier Anglaret
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

7.  Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.

Authors:  Olivia Keiser; Kathryn Anastos; Mauro Schechter; Eric Balestre; Landon Myer; Andrew Boulle; David Bangsberg; Hapsatou Touré; Paula Braitstein; Eduardo Sprinz; Denis Nash; Mina Hosseinipour; François Dabis; Margaret May; Martin W G Brinkhof; Matthias Egger
Journal:  Trop Med Int Health       Date:  2008-03-27       Impact factor: 2.622

8.  Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand: implications for vaccine trials.

Authors:  Kate Buchacz; Dale J Hu; Suphak Vanichseni; Philip A Mock; Thanyanan Chaowanachan; La-ong Srisuwanvilai; Roman Gvetadze; Frits Van Griensven; Jordan W Tappero; Dwip Kitayaporn; Jaranit Kaewkungwal; Kachit Choopanya; Timothy D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

9.  Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy.

Authors:  Jim Todd; Judith R Glynn; Milly Marston; Tom Lutalo; Sam Biraro; Wambura Mwita; Vinai Suriyanon; Ram Rangsin; Kenrad E Nelson; Pam Sonnenberg; Dan Fitzgerald; Etienne Karita; Basia Zaba
Journal:  AIDS       Date:  2007-11       Impact factor: 4.177

10.  Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies.

Authors:  Simon Wandel; Matthias Egger; Ram Rangsin; Kenrad E Nelson; Caroline Costello; Charlotte Lewden; Tom Lutalo; Anthony Ndyanabo; Jim Todd; Lieve Van der Paal; Albert Minga; Marcel Zwahlen
Journal:  Sex Transm Infect       Date:  2008-08       Impact factor: 3.519

View more
  7 in total

1.  Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Authors:  Xavier Anglaret; Callie A Scott; Rochelle P Walensky; Eric Ouattara; Elena Losina; Raoul Moh; Jessica E Becker; Lauren Uhler; Christine Danel; Eugene Messou; Serge Eholié; Kenneth A Freedberg
Journal:  Antivir Ther       Date:  2012-07-18

2.  New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon.

Authors:  Jacques D A Ndawinz; Xavier Anglaret; Eric Delaporte; Sinata Koulla-Shiro; Delphine Gabillard; Albert Minga; Dominique Costagliola; Virginie Supervie
Journal:  Bull World Health Organ       Date:  2015-06-01       Impact factor: 9.408

3.  Model-based prediction of CD4 cells counts in HIV-infected adults on antiretroviral therapy in Northwest Ethiopia: A flexible mixed effects approach.

Authors:  Tadesse Awoke Ayele; Alemayehu Worku; Yigzaw Kebede; Khangelani Zuma; Adetayo Kasim; Ziv Shkedy
Journal:  PLoS One       Date:  2019-07-10       Impact factor: 3.240

4.  Getting more from heterogeneous HIV-1 surveillance data in a high immigration country: estimation of incidence and undiagnosed population size using multiple biomarkers.

Authors:  Federica Giardina; Ethan O Romero-Severson; Maria Axelsson; Veronica Svedhem; Thomas Leitner; Tom Britton; Jan Albert
Journal:  Int J Epidemiol       Date:  2019-12-01       Impact factor: 7.196

5.  Optimal starting point for antiretroviral HIV treatment in a town in Cameroon: a randomised controlled study.

Authors:  Knut Holtedahl; Daniel Salpou; Tonje Braaten; Zogoi Berved
Journal:  BMC Public Health       Date:  2014-08-10       Impact factor: 3.295

6.  Estimating time of HIV-1 infection from next-generation sequence diversity.

Authors:  Vadim Puller; Richard Neher; Jan Albert
Journal:  PLoS Comput Biol       Date:  2017-10-02       Impact factor: 4.475

7.  Rapid Clinical Progression and Its Correlates Among Acute HIV Infected Men Who Have Sex With Men in China: Findings From a 5-Year Multicenter Prospective Cohort Study.

Authors:  Jing Zhang; Xiao-Jie Huang; Wei-Ming Tang; Zhenxing Chu; Qinghai Hu; Jing Liu; Haibo Ding; Xiaoxu Han; Zining Zhang; Yong-Jun Jiang; Wenqing Geng; Wei Xia; Junjie Xu; Hong Shang
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.